Amirreza Zobdeh

Mr. Amirreza Zobdeh

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2023 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
AZAmirreza Zobdeh
Amirreza Zobdeh
RBRazieh Bandari
Razieh Bandari
MHMajideh Heravi-Karimooi
Majideh Heravi-Karimooi
MMMaryam Mashayekh
Maryam Mashayekh
MHMaryam Hazrati
Maryam Hazrati
Ali MontazeriAli Montazeri
Ali Montazeri
Background: The present study aimed to design and determine the psychometric properties of a short-form questionnaire to investigate the domestic elder abuse. Methods: This study consisted of two phases: in phase 1 we employed a modified Delphi approach with 18 participants. Consequently, content and face validity, and item analysis were applied. In Phase 2 we evaluated structural validity and convergent validity. Reliability was assessed by looking at internal consistency, stability, and absolute reliability. Results: The findings led to the development of a 27-items short form of domestic elder abuse in four domains that jointly accounted for 74.14% of the variance observed. The short form showed high internal consistency (Cronbach’s alpha = 0.93) and significantly correlated (r = 0.91; p < 0.001 for both scales) with the comprehensive (49-item) domestic elder abuse. Conclusion: The short form of domestic elder abuse was found to be reliable and valid as the longer version. The short form of domestic elder abuse could lessen the burden on respondents.

24 November 2024 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
AZAmirreza Zobdeh
Amirreza Zobdeh
Daniel Jake HoyleDaniel Jake Hoyle
Daniel Jake Hoyle
PSPankti Shastri
Pankti Shastri
WBWoldesellassie M. Bezabhe
Woldesellassie M. Bezabhe
Gregory PetersonGregory Peterson
Gregory Peterson

19 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AZAmirreza Zobdeh
Amirreza Zobdeh
Gregory PetersonGregory Peterson
Gregory Peterson
WBWoldesellassie M. Bezabhe
Woldesellassie M. Bezabhe
PSPankti Shastri
Pankti Shastri
Daniel Jake HoyleDaniel Jake Hoyle
Daniel Jake Hoyle
Background/Objectives: Atrial fibrillation (AF), the most common cardiac arrhythmia, significantly elevates the risk of new-onset heart failure (HF). We aimed to systematically map and appraise available evidence on drug therapies and incident HF in patients with AF. Methods: We searched Medline, Embase, Cochrane Central Register of Controlled Trials, and Scopus up to 16 September 2026 for relevant randomized controlled trials (RCTs), sub-analyses of RCTs, and observational/cohort studies. Results: Seventeen studies (397,991 participants) were included. The only randomized signal came from a prespecified subgroup of the ACTIVE-I trial, in which irbesartan was associated with fewer first HF hospitalizations than the placebo (HR 0.81, 95% CI 0.69–0.96; moderate certainty). Observational studies showed an association with lower first HF hospitalization for sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (pooled HR 0.68, 95% CI 0.48–0.95; two studies; low certainty) and lower incident HF diagnosis in a larger cohort that included patients without diabetes (HR 0.86, 95% CI 0.82–0.89). The remaining cohort evidence largely reflected prescribing patterns rather than drug effects. Statins showed an inconsistent association. The higher HF incidence among users of diuretics, mineralocorticoid receptor antagonists, digoxin and renin-angiotensin system inhibitors was consistent with confounding by indication (very low certainty). Conclusions: Evidence on drug therapies to prevent HF in AF is limited to one randomized subgroup signal for irbesartan. The remaining findings were associations rather than demonstrated treatment effects. High-quality research, including RCTs in broader AF populations, is needed. PROSPERO Registration: CRD42024587926.